Your session is about to expire
← Back to Search
Observational - Healthy Control Arm for Psychosis
Summary
Antipsychotic (AP) medications are currently the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth, with an established two-fold increase in standardized mortality ratio attributable to cardiovascular disease in this population. However, APs have been associated with common and serious metabolic adverse effects including weight gain and diabetes, to which youth are disproportionally vulnerable. The Gut Microbiome (GMB) has been suggested as a potential target warranting further study as a mechanism of AP induced weight gain and has also been linked directly with cognition and behavior. It is hypothesized that there will be changes in the gut microbiome overtime with treatment correlated with metabolic measures and that APs will produce changes in glucose tolerance, insulin sensitivity, adipokines, glucagon like peptide (GLP)-1, lipids, fasting glucose, body weight, and cognition.
- Psychosis
- Schizophrenia
Timeline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 356 Patients • NCT00048997Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger